Genome-wide association studies (GWAS) have identified key genetic risk loci for non-alcoholic fatty liver disease (NAFLD), metabolic dysfunction–associated steatohepatitis (MASH), liver fibrosis, and hepatocellular carcinoma (HCC) with high precision. Working directly in primary human hepatocytes and hepatic stellate cells that carry these exact, genotype-confirmed risk alleles is now possible.

ScienCell offers validated lots of both cell types with defined variants in PNPLA3, TM6SF2, HSD17B13, enabling true genotype–phenotype correlation studies that are not feasible with immortalized cell lines or genotype-unknown primary cells.

Human Primary Liver Cells Genotyped Variants

Human Hepatocytes
(Cat. No. 5200)
Genotyped for PNPLA3 (rs738409 & rs738408), TM6SF2 (rs58542926), and HSD17B13 (rs72613567). Key metabolic functions retained.

Human Hepatic Stellate Cells
(Cat. No. 5300)
Genotyped across the same three loci. Select lots include the homozygous risk-allele background for PNPLA3, critical for fibrosis mechanism studies.

Why Genotype-Defined Primary Cells?

Research Applications

• NAFLD/MASLD & MASH disease modeling
• Hepatic stellate cell activation & fibrogenesis
• Genotype-stratified drug efficacy screening
• Lipid metabolism & VLDL secretion studies
• Hepatotoxicity & safety pharmacology
• Biomarker & transcriptomic profiling
• Multicellular co-culture & organoid models
• Precision medicine & target validation

For information on available genotypes, assistance selecting the right cells, or inquiries about additional genotypes and cell types, please contact us at info@sciencellonline.com, or call 1.877.602.8549 and we’re happy to support your project.